I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Discontinuation of pembrolizumab for advanced urothelial ca..:
Katsuhiro Ito
;
Yuki Kita
;
Akira Yokomizo
...
https://doi.org/10.1002/cam4.5057. , 2023
Link:
https://doi.org/10.1002/cam4.5057
RT Journal T1
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:8233fb43169641d5938784ae9c87acbf&Exemplar=1&LAN=DE A1 Katsuhiro Ito A1 Yuki Kita A1 Akira Yokomizo A1 Jun Miki A1 Yuko Yoshio A1 Hiroaki Matsumoto A1 Takehiko Segawa A1 Takashi Karashima A1 Naotaka Nishiyama A1 Kazuto Imai A1 Shigetaka Suekane A1 Seiji Nagasawa A1 Shin Higashi A1 Hiroyuki Nishiyama A1 Hiroshi Kitamura A1 Takashi Kobayashi PB Wiley YR 2023 K1 carcinoma K1 transitional cell K1 duration of therapy K1 immune checkpoint inhibitors K1 immunotherapy K1 pembrolizumab K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens K1 RC254-282 JF https://doi.org/10.1002/cam4.5057 LK http://dx.doi.org/https://doi.org/10.1002/cam4.5057 DO https://doi.org/10.1002/cam4.5057 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)